Reports Q4 revenue $2.39B, consensus $2.47B. “Oscar reported positive full year 2024 results, capping the strongest year of financial performance in Company history,” said Mark Bertolini, CEO of Oscar Health (OSCR). “We reported both Adjusted EBITDA and net income profitability – two significant milestones. Our strong top and bottom line performance, all-time-high-membership, and consistent execution demonstrate our ability to deliver sustained profitable growth.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OSCR:
- Oscar Health options imply 11.6% move in share price post-earnings
- Oscar Health, Inc. (OSCR) Q4 Earnings Cheat Sheet
- Oscar Health call volume above normal and directionally bullish
- Oscar Health put volume heavy and directionally bearish
- Elevance Health price target lowered to $458 from $529 at Jefferies